Media.Player

In vitro production of human bone tissue from pluripotent cells in perfusion culture

Summary

Lead Inventors: Gordana Vunjak Novakovic, Ph.D.; Darja Marolt, Ph.D.Problem or Unmet Need:Reconstruction of human bone to address defects arising due to injury, congenital malformations, or disease currently is effected using autologous tissue grafts (i.e., living bone taken from other parts of a patient's skeleton) or biomaterial scaffolds impregnated with substances that encourage formation of new tissue by endogenous progenitor cells via cell homing. These techniques are hampered by a number of limitations, including autologous tissue harvesting difficulties, graft donor site morbidity, and difficulties associated with the reconstruction of large grafts using cell homing.The technology is a novel staged protocol for in vitro production of living human bone tissue from human embryonic stem cells (hESCs). This protocol involves the seeding of osteoconductive scaffolds (e.g., decellularized bone) with osteogenic progenitor cells induced from hESCs. Large pieces of bone tissue can be developed by perfusion of the cell-seeded scaffolds in a bioreactor.

Technology Benefits

* By enabling the production of living tissue grafts of arbitrary size, the technology can obviate the difficulties and limitations associated with autologous tissue grafting, allogeneic transplantation, and prosthetic implants.

Technology Application

* The technology can be used to provide an unlimited supply of functional human bone grafts for transplantation or testing of drugs affecting bone formation.* The technology can potentially be extended to human induced pluripotent stem (hiPS) cells in order to develop autologous bone grafts with vascular components, and composite grafts interfacing bone with adjacent tissues.

Detailed Technology Description

The technology is a novel staged protocol for in vitro production of living human bone tissue from human embryonic stem cells (hESCs). This protocol involves the seeding of osteoconductive scaffolds (e.g., decellularized bone) with osteogenic progeni...

*Abstract

None

*Inquiry

Donna See Columbia Technology Ventures Tel: (212) 854-8444 Email: TechTransfer@columbia.edu

*IR

2846

*Principal Investigator

*Publications

None

Country/Region

USA